This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Niacin Causes Serious Unexpected Side-effects, But No Worthwhile Benefits, For Patients Who Are At Increased Risk Of Heart Attacks And Strokes

SAN FRANCISCO, March 9, 2013 /PRNewswire/ --

Adding extended-release (ER) niacin to statins does not reduce the chances of high risk patients having a heart attack or stroke, Oxford University scientists leading the HPS2-THRIVE study have revealed at the ACC conference in San Francisco today.

In addition, the researchers report that the use of ER niacin causes a significant number of different types of serious side effect. Some of these side effects were already known to be caused by niacin, but some of them were unexpected.  

Niacin has been used for many years to modify cholesterol levels in people at high risk of heart attacks and strokes. It is particularly widely used in the United States, although there is limited evidence that it reduces the risk of cardiovascular outcomes (e.g. heart attacks and strokes), especially when added to current cholesterol-lowering therapy. Flushing is a common side effect that reduces compliance with niacin therapy. In HPS2-THRIVE, the ER niacin was combined with a new drug called laropiprant (which is a prostaglandin receptor blocker) in order to reduce problems due to flushing.

Over 25,000 patients with pre-existing cardiovascular disease from the UK, Scandinavia and China were recruited into HPS2-THRIVE. They were all given simvastatin (plus, when required, another cholesterol-lowering drug called ezetimibe) as background treatment to reduce their initial cholesterol level. They were then assigned at random to receive either the ER niacin with laropiprant or a dummy (placebo) treatment for about 4 years. HPS2-THRIVE is, by far, the biggest study of niacin ever undertaken. The use of randomised treatment assignment, and the large size and long duration, make the findings very reliable.

The primary aim of the HPS2-THRIVE trial was to find out whether adding niacin to currently standard treatments (including effective statin-based cholesterol-lowering therapy) would produce worthwhile reductions in the risks of heart attacks, strokes or other cardiovascular outcomes.  Among those who took the ER niacin combination 13.2% suffered a heart attack, stroke or had an arterial procedure compared with 13.7% in those who took the dummy (placebo) tablets  ΜΆ  a small but not clearly significant difference.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,661.81 -68.30 -0.39%
S&P 500 2,066.22 -10.56 -0.51%
NASDAQ 4,985.4960 -23.7180 -0.47%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs